NMTR
9 Meters Biopharma, Inc. [NMTR] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
NMTR Stock Summary
In the News
NMTR Financial details
Company Rating
Neutral
Market Cap
1.04M
Income
-49.8M
Revenue
0
Book val./share
-0.46
Cash/share
0.51
Dividend
-
Dividend %
-
Employees
10
Optionable
No
Shortable
Yes
Earnings
14 Aug 2023
P/E
-0.02
Forward P/E
-
PEG
-0.01
P/S
-
P/B
-0.16
P/C
-
P/FCF
-0.03
Quick Ratio
0.45
Current Ratio
0.59
Debt / Equity
-0.82
LT Debt / Equity
-0.01
-
-
EPS (TTM)
-3.79
EPS next Y
-
EPS next Q
-
EPS this Y
15.84%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
14.85%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
0%
Inst Trans
0%
ROA
-535%
ROE
-629%
ROC
6.93%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.0715-6.56
52W High
-
52W Low
-
RSI
-
Rel Volume
10.3
Avg Volume
446.11K
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
1.47712
-
-
Volatility
0.03%, 0.03%
Prev Close
-
Price
-
Change
-
NMTR Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -19.52 | -17.33 | -12.41 | -3.03 | -3.51 | |
| Operating cash flow per share | -12.25 | -10.78 | -3.67 | -2.43 | -2.87 | |
| Free cash flow per share | -12.26 | -10.79 | -4.28 | -2.63 | -2.87 | |
| Cash per share | 4.63 | 2.76 | 7.17 | 3.87 | 0.98 | |
| Book value per share | -2.96 | -5.77 | 6.09 | 3.42 | 0.19 | |
| Tangible book value per share | -2.96 | -5.77 | 6.09 | 3.42 | 0.19 | |
| Share holders equity per share | -2.96 | -5.77 | 6.09 | 3.42 | 0.19 | |
| Interest debt per share | 9.17 | 3.03 | 0.81 | 0.02 | 1.73 | |
| Market cap | 57.2M | 18.56M | 90.75M | 237.93M | 16.32M | |
| Enterprise value | 56.67M | 17.2M | 53.13M | 191.11M | 23.41M | |
| P/E ratio | -2.37 | -0.64 | -1.38 | -6.46 | -0.36 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -3.77 | -1.03 | -4.68 | -8.07 | -0.44 | |
| PFCF ratio | -3.77 | -1.03 | -4.02 | -7.44 | -0.44 | |
| P/B Ratio | -15.63 | -1.93 | 2.82 | 5.72 | 6.8 | |
| PTB ratio | -15.63 | -1.93 | 2.82 | 5.72 | 6.8 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -3.14 | -0.71 | -2.48 | -6.04 | -0.56 | |
| EV to operating cash flow | -3.74 | -0.96 | -2.74 | -6.48 | -0.63 | |
| EV to free cash flow | -3.73 | -0.96 | -2.35 | -5.98 | -0.63 | |
| Earnings yield | -0.42 | -1.56 | -0.72 | -0.15 | -2.79 | |
| Free cash flow yield | -0.27 | -0.97 | -0.25 | -0.13 | -2.28 | |
| Debt to equity | -1.42 | -0.34 | 0.01 | 0 | 8.22 | |
| Debt to assets | 0.81 | 0.61 | 0.01 | 0 | 0.6 | |
| Net debt to EBITDA | 0.03 | 0.06 | 1.76 | 1.48 | -0.17 | |
| Current ratio | 0.63 | 0.35 | 5.68 | 5.91 | 1.08 | |
| Interest coverage | -2.96 | -14 | -15.05 | -779.05 | -15.75 | |
| Income quality | 0.63 | 0.66 | 0.32 | 0.8 | 0.85 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0.16 | 0.08 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -0.71 | -0.55 | -172.35 | -330.87 | -0.33 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 36.02 | 47.43 | 41.22 | 15.27 | 3.83 | |
| ROIC | -11.96 | 4.3 | -1.99 | -0.88 | -1.96 | |
| Return on tangible assets | -3.74 | -5.45 | -1.67 | -0.73 | -1.37 | |
| Graham Net | -3.54 | -6.19 | 5.84 | 3.16 | -1.4 | |
| Working capital | -3.7M | -9.69M | 32.08M | 41.53M | 2.32M | |
| Tangible asset value | -3.66M | -9.61M | 32.14M | 41.6M | 2.4M | |
| Net current asset value | -3.7M | -9.69M | 31.91M | 41.42M | 2.27M | |
| Invested capital | -1.42 | -0.34 | 0.01 | 0 | 8.22 | |
| Average receivables | 45K | 0 | 0 | 0 | 0 | |
| Average payables | 2.03M | 3.75M | 2.69M | 1.96M | 3.74M | |
| Average inventory | 50.5K | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | 6.6 | 3 | -2.04 | -0.89 | -18.96 | |
| Capex per share | -0.01 | -0.01 | -0.6 | -0.21 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-03-31 for Q1
| Metric | History | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -0.88 | -0.85 | -0.77 | -1.01 | -1.16 | |
| Operating cash flow per share | -0.75 | -0.6 | -0.77 | -0.75 | -0.72 | |
| Free cash flow per share | -0.76 | -0.6 | -0.77 | -0.75 | -0.72 | |
| Cash per share | 2.88 | 2.27 | 1.22 | 0.98 | 0.51 | |
| Book value per share | 2.4 | 1.71 | 1.04 | 0.19 | -0.46 | |
| Tangible book value per share | 2.4 | 1.71 | 1.04 | 0.19 | -0.46 | |
| Share holders equity per share | 2.4 | 1.71 | 1.04 | 0.19 | -0.46 | |
| Interest debt per share | 0.01 | 0.02 | 1.49 | 1.66 | 0.44 | |
| Market cap | 154.76M | 67.55M | 55.71M | 16.32M | 18.89M | |
| Enterprise value | 117.67M | 38.23M | 58.37M | 23.41M | 17.12M | |
| P/E ratio | -3.41 | -1.53 | -1.39 | -0.31 | -0.3 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -15.88 | -8.68 | -5.59 | -1.68 | -1.94 | |
| PFCF ratio | -15.87 | -8.68 | -5.59 | -1.68 | -1.94 | |
| P/B Ratio | 5 | 3.06 | 4.14 | 6.8 | -3 | |
| PTB ratio | 5 | 3.06 | 4.14 | 6.8 | -3 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -10.37 | -3.44 | -6.8 | -2.24 | -1.36 | |
| EV to operating cash flow | -12.07 | -4.91 | -5.85 | -2.4 | -1.76 | |
| EV to free cash flow | -12.07 | -4.91 | -5.85 | -2.4 | -1.76 | |
| Earnings yield | -0.07 | -0.16 | -0.18 | -0.8 | -0.83 | |
| Free cash flow yield | -0.06 | -0.12 | -0.18 | -0.6 | -0.52 | |
| Debt to equity | 0.01 | 0.01 | 1.38 | 8.22 | -0.82 | |
| Debt to assets | 0 | 0 | 0.44 | 0.6 | 0.56 | |
| Net debt to EBITDA | 3.27 | 2.63 | -0.31 | -0.68 | 0.14 | |
| Current ratio | 4.75 | 3.36 | 1.43 | 1.08 | 0.59 | |
| Interest coverage | -37.38K | -171.4 | -10.29 | -5.9 | -16.99 | |
| Income quality | 0.86 | 0.7 | 1.07 | 0.82 | 0.7 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -1.75 | 0 | 0 | -1.12 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 6.88 | 5.73 | 4.25 | 2.05 | 3.47 | |
| ROIC | -0.36 | -0.5 | -0.29 | -0.53 | 14.04 | |
| Return on tangible assets | -0.29 | -0.35 | -0.24 | -0.39 | -1.69 | |
| Graham Net | 2.24 | 1.55 | -0.99 | -1.4 | -0.64 | |
| Working capital | 30.86M | 22.01M | 5.59M | 2.32M | -6.38M | |
| Tangible asset value | 30.94M | 22.09M | 13.46M | 2.4M | -6.3M | |
| Net current asset value | 30.77M | 21.93M | -10.22M | 2.27M | -6.41M | |
| Invested capital | 0.01 | 0.01 | 1.38 | 8.22 | -0.82 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 2.17M | 2.12M | 1.88M | 3.25M | 4.64M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.37 | -0.5 | -0.74 | -5.43 | 2.49 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
NMTR Frequently Asked Questions
What is 9 Meters Biopharma, Inc. stock symbol ?
9 Meters Biopharma, Inc. is a US stock , located in Raleigh of Nc and trading under the symbol NMTR
What is 9 Meters Biopharma, Inc. stock quote today ?
9 Meters Biopharma, Inc. stock price is $- today.
Is 9 Meters Biopharma, Inc. stock public?
Yes, 9 Meters Biopharma, Inc. is a publicly traded company.
Company Profile
- Volume Average 446.11K
- Market Capitalization 1.04M
- Employee 10
- CEO Ms. Bethany Sensenig C.M.A., M.B.A.
- Headquarters Raleigh,NC,US
- IPO Date 2016-07-11
-
Website
https://www.9meters.com 
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease, as well as in Phase IIa clinical trial for treatment of multi-system inflammatory syndrome; and Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 2 clinical trial to treat short bowel syndrome. It also develops NM-102, a small molecule peptide; NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease; NM-136, a humanized monoclonal antibody for targeted obesity disorders; and NM-004, a double-cleaved mesalamine with an immunomodulator for rare and/or orphan indications. The company is based in Raleigh, North Carolina.
